ReviewCancers2026
Calcium-Orchestrated Vascular Collapse in Cancer Therapy: Mechanisms, Nanotherapeutic Platforms, and Translational Perspectives.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy is increasingly focused on manipulating the tumor microenvironment rather than directly eradicating malignant cells. Vascular-targeting strategies are emerging, and calcium-mediated vascular disruption is an exciting approach through which rapid and irreversible blood flow shutdown can be achieved. Here, we overview the molecular and physiological basis of calcium signaling in vascular homeostasis and outline how unregulated calcium dysfunctions in endothelial cells compromise their functionality and represent therapeutic opportunities. Elevation of intracellular calcium concentrations in endothelial cells promotes their dysfunction, coagulation, mitochondrial collapse, oxidative stress, and ultimately apoptosis, resulting in catastrophic vascular depletion and secondary necrosis that follows such collapse. A promising area of calcium-mediated attack is the emergence of exciting nanotechnologies that result in the development of calcium phosphate, calcium carbonate, and calcium peroxide nanoparticles, exploiting the enhanced permeability and retention effect of nanoparticle therapeutics to achieve selective tumor accumulation and controlled calcium release. Indeed, hybrid therapeutic platforms that couple calcium dysregulation with chemotherapy, photodynamic therapy, sonodynamic therapy, immunotherapy, or thermal ablation can exhibit pronounced antitumor effects through synergistic means. There is good preclinical evidence for the feasibility of vascular collapse mediated via calcium dysregulation. The transition of calcium to the clinic faces hurdles in relation to biosafety, how to achieve precise delivery, pharmacokinetics, and regulatory harmonization. Compared to traditional vascular disrupting agents and anti-angiogenic therapies, calcium modalities can provide rapid occlusion of vessels, are less prone to resistance development, and potentially have less systemic toxicity. Overall, calcium-mediated vascular collapse is thus an exciting next-generation technology for the vascular-targeted treatment of cancer, and likely to play an important role in precision oncology therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.